Oliver Wyman October 24, 2024
Five trends are changing the landscape for corporate venture capital among pharmaceutical companies.
Corporate venture capital can be a boon for the pharmaceutical industry. It gives incumbent pharmaceutical companies access to cutting-edge innovations, lowers risk for research and development through co-investment, and diversifies pipelines geographically and technologically. For early-stage biotechnology companies, it provides essential funding, external validation, and access to invaluable resources, talent, and infrastructure.
Still, companies must be strategic in knowing when, how, and why leverage these types of investments. We explored five key hypotheses to test recent shifts in pharmaceutical venture capital flows, providing insights into the current state and future trajectory of capital flow:
Hypothesis 1: Investments Have Rebounded Following a Post-Pandemic Drop
Oliver Wyman Assessment: True
...Today's Sponsors
Today's Sponsor